Business Across Borders 2021

Experts’ Views 27 Business Across Borders 2021 Metrochem API Private Limited Dr. Nandepu Venkateswara Rao Chairman & Managing Director Kindly take us through your company’s journey and some of its key milestones. We started Metrochem with a grand vision of being the “most preferred supply partner to pharmaceutical customers worldwide.” We felt a responsibility to deliver high quality pharmaceutical products. We began our humble journey with a single API unit manufacturing two APIs in the year 2004. We quickly backward integrated to intermediates by starting our Intermediate facility in the year 2005. We kept on pushing ourselves to continuously improve and achieve our vision of providing reliable end to end pharmaceutical support in high growth, high impact therapeutic areas. I am very proud to share that our manufacturing facilities are approved by several international regulatory bodies such as ISO 9001-2015, USFDA, WHO: GMP, Cofepris, PMDA, and KFDA. Adapting quickly to the ever-evolving demands, we have emerged as one of the fastest growing organization in the pharmaceutical industry across India. Recognizing our efforts, Department of Pharmaceuticals, Government of India, awarded Metrochem the prestigious INDIA PHARMA BULK DRUG COMPANY OF THE YEAR AWARD 2021. To extend our impeccable service to the global markets and to meet the increasing demand across our portfolio, we initiated the construction of our Vizag facility in 2012. It’s a Greenfield project spanning across 10 acres. It was built as a gateway to Metrochem’s foray into the regulatory markets. The plant has a reactor volume of 1250KL with a range of 0.5KL to 30KL. Commercial production commenced in late 2017. Up to 2020, we filed 25 USDMFs and 15 CEPs from this facility. I have PhD in Organic Chemistry and when it comes to R&D, I never say no to any project that knocks our door. I can gladly claim that Metrochem is a research-driven pharma organization. This has helped Metrochem expand its portfolio from 2 to 300+ and will keep this going. All our R&D activities take place in the R&D Center in Jeedimetla, Hyderabad where over 200 scientists and their teams work tirelessly to synthesize novel, efficient routes for products across multiple therapeutic categories. We have recently invested $5 million in upgrading our Analytical R&D. Metrochem also has a formulation R&D and a process R&D focusing on the application of flow chemistry. We are number one in domestic anti- ulcerative segment. We make about 10000 tons of APIs across different therapeutic segments. Our reactor capacity stands at 3000KL with a range of 0.5KL to 30KL. Metrochem’s greatest strength is its workforce. We have talented workforce of more than 3000 employees. Our able marketing team is committed to providing you best in class customer service. What are the key products and services that the company offers? W e are one of the largest manufacturers of products across therapeutic categories such as Antiulceratives, Antifungals, Antidiabetics and Antihistamines. Our strong vertical integration setup enables us to offer Intermediates, APIs and Pellets of the products to fulfil different business needs of our customers. Our R&D team continuously works on developing and adding more new products to our portfolio on a regular basis. What are some of the company’s key overseas markets? Which are some of the newer markets you are targeting? Our key export markets include LATAM, MENA, South East Asia, China, Bangladesh and Pakistan. We have filed 25 USDMFs and 15 CEPs so far from our flagship facility in Vizag through which we are hoping to enter regulated markets, USA and Europe within the financial year 2021-22. Dun & Bradstreet